IQVIA Holdings Inc Überblick
Branche: Diagnostics & Research
Sektor: Healthcare
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and decentralized clinical trials, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was incorporated in 2016 and is headquartered in Durham, North Carolina. IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development S
Research-Überblick
Letztes Berichtsdatum 2026-07-28Diese Mavefund-Research-Seite bündelt geprüfte Informationen zu IQVIA Holdings Inc (IQV): Unternehmensprofil, Kursverlauf, verknüpfte Primärquellen, verfügbare Finanzberichte, Research-Signale und zu prüfende Risiken.
- Börsennotierung
- IQV · NYSE · MIC XNYS
- Land
- United States
- Handelswährung
- USD
- Branche
- Diagnostics & Research
- Finanzdaten
- Jahres- und Zwischenabschlüsse verfügbar
- Letzte Primärquelle
- SEC EDGAR · veröffentlicht 2026-07-28
- Letzter Bericht · SEC EDGAR Veröffentlicht 2026-07-28
- Registrierungsdokument
Die Abdeckung wird automatisch aktualisiert und erst nach einer Datenintegritätsprüfung veröffentlicht. Nur Research-Unterstützung; keine persönliche Anlageberatung.
Mavefund ordnet die verfügbaren Fundamentaldaten, Bewertungskennzahlen und Risikofaktoren von IQVIA Holdings Inc für einen nachvollziehbaren Research-Prozess ein.
Score
Veröffentlichte Ergebnisse
Was das Unternehmen berichtet hat – mit kompakter Quellenangabe.
Quarterly result summary
Revenue was $4,368M (+8.7% YoY); EPS was $1.53 (reported).
Was sich verändert hat
- Revenue +8.7% YoY to $4,368M; EPS reported to $1.53.
- Capital return update: free cash flow $360M.
- Operating income +0% YoY to $506M.
Guidance / outlook
The company expects approximately $9.2 billion of this backlog to convert to revenue in the next twelve months, representing growth of 7.5% year-over-year.
Source: SEC EDGAR company-filed earnings materials. Dates and source identifiers are retained for verification; review the original filing before relying on extracted report details.
Weitere aktuelle Ergebnisunterlagen
Geprüfte Signal-Evidenz
Aktuelle Nachrichten
Unternehmensrelevante Artikel aus Quellen, die die Relevanz- und Zuverlässigkeitsprüfung des Mave Signals bestehen.
How Strong Q2 Beat And Raised 2026 Guidance At IQVIA Holdings (IQV) Has Changed Its Investment Story
Headline from Yahoo Finance: How Strong Q2 Beat And Raised 2026 Guidance At IQVIA Holdings (IQV) Has Changed Its Investment Story.
Why Is IQVIA (IQV) Up 5.6% Since Last Earnings Report?
Headline from Yahoo Finance: Why Is IQVIA (IQV) Up 5.6% Since Last Earnings Report?
IQVIA Holdings (IQV) Q1 2026 Earnings Call Transcript
Headline from Fortune: IQVIA Holdings (IQV) Q1 2026 Earnings Call Transcript.
IQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and Healthcare
Headline from Business Wire: IQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and Healthcare.
Here's Why You Should Retain IQVIA Stock in Your Portfolio Now
Headline from Yahoo Finance: Here's Why You Should Retain IQVIA Stock in Your Portfolio Now.
Here's Why You Should Retain IQVIA Stock in Your Portfolio Now
Headline from Yahoo Finance Singapore: Here's Why You Should Retain IQVIA Stock in Your Portfolio Now.
Gewinn je Aktie
Eigenkapitalrendite
Eigenkapitalrendite
Unternehmen —
Sektormedian —
Eigenkapitalrendite
Unternehmen —
Sektormedian —
Eigenkapitalrendite
Unternehmen —
Sektormedian —
Eigenkapitalrendite
Unternehmen —
Sektormedian —
Kennzahlen-Chart vorübergehend nicht verfügbar.
Nettomarge
Nettomarge
Unternehmen —
Sektormedian —
Nettomarge
Unternehmen —
Sektormedian —
Nettomarge
Unternehmen —
Sektormedian —
Nettomarge
Unternehmen —
Sektormedian —
Kennzahlen-Chart vorübergehend nicht verfügbar.
Verschuldung
Verschuldungsgrad
Unternehmen —
Sektormedian —
Verschuldungsgrad
Unternehmen —
Sektormedian —
Verschuldungsgrad
Unternehmen —
Sektormedian —
Verschuldungsgrad
Unternehmen —
Sektormedian —
Kennzahlen-Chart vorübergehend nicht verfügbar.
Finanzberichte
Vom Unternehmen veröffentlichte Berichtsdaten, strukturiert und mit der Originalquelle verknüpft.
Quellendetails werden mit den Berichtsdaten geladen. Die Werte sind standardisierte Unternehmensangaben zur Research-Unterstützung, keine persönliche Anlageberatung.